Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (2168)	2/2/2000 12:55:00 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

<Most clinicians would laugh at a trial like this.> I disagree, but who cares anyway? Even if every clinician in the world snubbed Zicam, Gum Tech could easily reach my $75 million sales estimate. <Since when does one, and only one, profitable quarter make any company a good long term investment?> Since when does a company whose sales are growing 100%+ YTY, and has not one, but two new and potentially blockbuster products on the market (Zicam), or ready to hit the market (nicotine gum), make a good short sale?